News

WODA is the winner of the 2023 Go Global Awards in the category of Collaborative Industry Partnership!

We are overjoyed with this remarkable achievement, especially since it is rigorously judged by a panel of international business experts.

The Saudi Food and Drug Authority has recently issued new guidelines for orphan drug designation, with a positive impact on companies and patients.

Specialised Therapeutics to represent WODA in Australia, New Zealand and across Southeast Asia (ANZSEA)

Companies join forces to introduce PKU GOLIKE Plus® 3-16, a breakthrough treatment for phenylketonuria (PKU), in the Middle East.

The addition of three new members – RareStone, CTS, and Path Pharma – brings the total number of countries covered by WODA to 76.

A long-term, multi-territorial distribution agreement with Theratechnologies Inc. ("Theratechnologies") for EGRIFTA SV® covers 41 countries.

WODA Alliance partners with Decisive Consulting to enhance access & pricing support for rare diseases & specialized therapeutics globally.

EffRx, Medis, Orpharm, OrphanDC & Vector Pharma form World Orphan Drug Alliance to support rare disease & specialized therapeutics globally.